Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of primary peritoneal carcinoma

Main Article Content

Armando Sardi *
Arkadii Sipok
Teresa P. Díaz-Montes
Michelle Sittig
Carol Nieroda
Kimberley Studeman
Vadim Gushchin
(*) Corresponding Author:
Armando Sardi | asardi@mdmercy.com

Abstract

Primary peritoneal carcinoma (PPC) is rare tumor, traditionally treated with surgical debulking and systemic chemotherapy (SC) with 30% five-year survival rate. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) may improve long-term survival. Thirty patients with PPC were identified. Twenty-three patients underwent CRS/HIPEC as initial treatment (group I) and 7 for recurrent disease (group II). Peritoneal cancer index (PCI), cytoreduction scores (CC), overall survival (OS) and progressionfree survival (PFS) were estimated using Kaplan-Meier survival analysis. FIGO stages II/III/IV at diagnosis were 2/20/7 (1 was not classified). Median time from diagnosis to CRS/HIPEC was 2 months and 8 months in groups I and II, respectively. PCI≥20 was seen in 16 (70%) and 4 (57%) in groups I and II, respectively. Complete cytoreduction (CC 0-1) was achieved in 30/32 (94%) CRS/HIPEC procedures. Median follow-up was 39 months (range: 11-250). PFS at 1, 3, 5-years was 80%, 75%, 59%, respectively. OS 1, 3, 5- years from CRS/HIPEC was 90%, 68%, 55%. CRS/HIPEC and adjuvant SC provides five-year survival rate higher than previously reported for PPC patients who received conventional therapy with surgical debulking and SC.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biographies

Armando Sardi, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

Director, The Institute for Cancer Care at Mercy

Chief, Surgical Oncology

Arkadii Sipok, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

Research Fellow

Surgical Oncology

Teresa P. Díaz-Montes, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

Gynecologic Oncologist

Associate Director, Segal Ovarian Cancer Institute

Michelle Sittig, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

RN

Surgical Oncology

Carol Nieroda, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

Surgical Onocology

Vadim Gushchin, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

Surgical Oncologist

Director, GI Oncology